Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: Radiologic–pathologic correlation of the response and disease-free survival depending on molecular subtype

Ciria, S. Cruz; Aragón, Fátima Jiménez; Mur, Carmen García; Cuesta, Helena; Bañeres, Belén Gros

doi:10.1016/j.rxeng.2012.10.002

Cited by 6 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumor grade reached a marginal significance with P = 0.0541. The accuracy was better in IDC than ILC + mixed type, better in mass than non‐mass morphology, better in HR‐negative than HR‐positive, better in HER2‐positive treated with trastuzumab than HER2‐negtaive; and these findings were consistent with results in several large series studies published recently . There was a weak, yet significant, association with the type of MRI scanner (1.5 T or 3 T).…”

Section: Discussionsupporting

confidence: 88%

“…Considering HR status alone, the mean MRI‐pathology size difference was 0.43 cm in HR‐negative cancer and 1.42 cm in HR‐positive cancer. Previous studies have shown that the diagnostic accuracy of MRI was better in HER‐2 positive than in HER‐2 negative cancer. Although it was noted that HER‐2 positive cancer might be less sensitive to taxane therapy than were HER‐2 negative tumors , the targeted therapy trastuzumab was very effective and were more likely to achieve pCR in HER‐2 positive than negative tumors , also to improve patient outcome .…”

Section: Discussionmentioning

confidence: 96%

“…In general, MRI diagnosis is more accurate in tumors that have a better response, and many studies have shown that the accuracy is related to combined HER2‐HR, or HER2‐luminal, biomarker status .…”

Section: Discussionmentioning

confidence: 99%

“…It has been shown that many factors, including the morphological response pattern (e.g., some tumors shrink concentrically, while others break apart into scattered tumor cells) , chemotherapeutic agents, NAC‐induced reactive changes within the tumor , and cellular and molecular characteristics of cancer are associated with diagnostic accuracy of MRI. In general, the accuracy of MRI is better in more aggressive tumors that are sensitive to chemotherapy, for example, triple negative tumors and HER2‐postive tumors that respond well to trastuzumab‐containing chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

Chen

Bahri

Mehta

et al. 2013

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives To investigate accuracy of magnetic resonance imaging (MRI) for measuring residual tumor size in breast cancer patients receiving neoadjuvant chemotherapy (NAC). Methods Ninety-eight patients were studied. Several MRI were performed during NAC for response monitoring, and the residual tumor size was measured on last MRI after completing NAC. Covariates, including age, tumor characteristics, biomarkers, NAC regimens, MRI scanners, and time from last MRI to operation, were analyzed. Univariate and Multivariate linear regression models were used to determine the predictive value of these covariates for MRI-pathology size discrepancy as the outcome measure. Results The mean (±SD) of the absolute difference between MRI and pathological residual tumor size was 1.0 ± 2.0 cm (range, 0–14 cm). Univariate regression analysis showed tumor type, morphology, HR status, HER2 status, and MRI scanner (1.5 T or 3.0 T) were significantly associated with MRI-pathology size discrepancy (all P < 0.05). Multivariate regression analyses demonstrated that only tumor type, tumor morphology, and biomarker status considering both HR and HER-2 were independent predictors (P = 0.0014, 0.0032, and 0.0286, respectively). Conclusion The accuracy of MRI in evaluating residual tumor size depends on tumor type, morphology, and biomarker status. The information may be considered in surgical planning for NAC patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

Chen

Bahri

Mehta

et al. 2013

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…In addition, the accuracy of imaging studies appears to be associated with breast cancer subtype and may be more accurate in assessing complete response in patients with HER2+ and TNBC. However, the combination of radiographic response after NAC and breast cancer subtype may be useful in stratifying patients with more advanced nodal disease for de‐escalation axillary surgery 21–26 …”

Section: Discussionmentioning

confidence: 99%

Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease

Goel

Yadegarynia

Rodgers

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Purpose Utilization of sentinel lymph node biopsy (SLNB) in breast cancer patients with positive nodes after neoadjuvant chemotherapy (NAC) has increased. We examine axillary response rates after NAC in patients with clinical N2‐3 disease to determine whether SLNB should be considered. Methods Breast cancer patients with clinical N2‐3 (AJCC 7th Edition) disease who received NAC followed by surgery were selected from our institutional tumor registry (2009–2018). Axillary response rates were assessed. Results Ninety‐nine patients with 100 breast cancers were identified: 59 N2 (59.0%) and 41 (41.0%) N3 disease; 82 (82.0%) treated with axillary lymph node dissection (ALND) and 18 (18.0%) SLNB. The majority (99.0%) received multiagent NAC. In patients undergoing ALND, cCR was observed in 20/82 patients (24.4%), pathologic complete response (pCR) in 15 patients (18.3%), and axillary pCR in 17 patients (20.7%). In patients with a cCR, pCR was identified in 60.0% and was most common in HER2+ patients (34.6%). Conclusion In this analysis of patients with clinical N2‐3 disease receiving NAC, 79.3% of patients had residual nodal disease at surgery. However, 60.0% of patients with a cCR also had a pCR. This provides the foundation to consider evaluating SLNB and less extensive axillary surgery in this select group.

show abstract

Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017

Su¹

2013

Breast Diseases: A Year Book Quarterly

View full text Add to dashboard Cite

Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: Radiologic–pathologic correlation of the response and disease-free survival depending on molecular subtype

Cited by 6 publications

References 14 publications

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease

Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017

Contact Info

Product

Resources

About